Skip to main content
Publications
Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A , Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial . J Clin Oncol. 2005 May 1;23(13):2946-54.
Douillard JY, Cella D, Natale R, Lynch TL, Lee C, Carbone D, Kay A, Wolf M M, Heyes AE , Ward J. Clinically meaningful improvement in disease-related symptoms by 'gefitinib' (Iressa, ZD1839) in patients with advanced non-small cell lung cancer: relationship between lung cancer subscale scores and radiographic response and survival . Presented at the European Cancer Conference 12; September 2003; September 2003. Copenhagen, Denmark.
LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox A, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A , Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors . Clin Cancer Res. 2003 Jun 1;9(6):2040-8.